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Diabetic retinopathy (DR) is the leading cause of blindness 
among patients 25–74 years old in industrialized countries. In the 
US alone, there are 29 million Americans living with diabetes 
mellitus (DM). The diagnosis, prevention, and treatment of DR 
thus represent a formidable challenge to the health-care system. 
Vigilant awareness of the continually evolving landscape of 
medical knowledge is critical to stemming this crisis. This review 
aims to provide important clinical updates in the management of 
DR.
Update on diagnosis
The cause of DR is multifactorial, and the primary contributor 
likely is chronic capillary non-perfusion and retinal ischemia. 
The signaling molecules insulin-like growth factor-1, platelet-
derived growth factor, angiopoietin, and most importantly vascular 
endothelial growth factor (VEGF) all play a role in the subsequent 
development of microangiopathy1. Recent evidence also sug-
gests that neurodegeneration is an early event in the pathogenesis 
of DR2,3. From a clinical standpoint, it is clear that the primary 
driving factor in this pathogenesis is uncontrolled blood glucose 
levels, with blood pressure and blood lipid composition also 
playing important roles. The diagnosis of DR remains clinical 
in nature. The gold standard for diagnosis is a dilated eye exam 
and serial fundus photos. Careful attention should be given to 
fundoscopic features of retinopathy, including microaneurysms, 
intraretinal hemorrhage, hard exudates, venous beading, intrareti-
nal microvascular anomalies (IRMAs), and, in the proliferative 
form, signs of neovascularization (NV). Several emerging tech-
nologies have demonstrated promise in assisting with the diagno-
sis of sight-threatening retinopathy. Researchers in collaboration 
with Google recently created a deep learning arti cial neural 
network trained to detect retinopathy based on fundoscopic 
images and achieved sensitivity of 97.5–96.1% and speci city of 
93.4–93.9% in detecting referable disease. In a hypothetical 
population with a prevalence of 8%, this translates to impres-
sive positive and negative predictive values of 99.8% and 99.6%, 
respectively4. Such automated systems hold the potential of 
offsetting the surge in demand for screening.
Update on imaging
Imaging modalities, especially optical coherence tomography 
(OCT) and uorescein angiography (FA), now play a crucial 
role in the diagnosis and management of complications of DR, 
particularly for diabetic macular edema (DME) and subtle 
NV, respectively. Newer modalities of OCT, including optical 
coherence tomography angiography (OCTA), hold the promise 
of further expanding the role of imaging. By using variation in 
phase and intensity of a light signal to infer vascular structures5, 
OCTA is able to resolve vascular details not achievable by con-
ventional FA, such as the deep and super cial capillary plexus6. 
Several authors have argued that OCTA is at least equal to FA in 
terms of ability to detect macular complications of DM, as it can 
detect areas of IRMA and NV7. Other microvascular changes seen 
on OCTA, speci cally decreasing capillary density, branching 
complexity, and increasing average vascular caliber, are all asso-
ciated with worsening DR (Figure 1)8. Intriguingly, some forms 
of retinal edema may be visible on OCTA but will not appear 
as uid pockets on OCT or late staining on FA9. Important 
drawbacks of the technology are the small eld of view and 
relative de ciency in detection of microaneuryms9.
Update on glycemic control and systemic factors
The Diabetes Control and Complications Trial (DCCT) and 
United Kingdom Prospective Diabetes Study demonstrated that 
glycemic control reduces microvascular complications for type 1 
and type 2 diabetics, respectively10. A recent 30-year follow-up of 
the DCCT, and more speci cally the Epidemiology of Diabetes 
Interventions and Complications study, also showed the impor-
tance of hemoglobin A1c (HbA1c) control, revealing a 50% risk 
reduction of retinopathy progression in intensive glycemic con-
trol patients, despite a subsequent increase (and corresponding 
decreasing in standard control patients) to a mean HbA1c value 
of 8%11,12. The Diabetic Retinopathy Clinical Research Network 
(DRCR.net) recently released the results of Protocol M, which 
showed that the addition of personalized risk assessments and 
education about glycemic control during ophthalmic of ce visits 
did not affect glycemic control13.
The Action to Control Cardiovascular Risk in Diabetes Follow-
on (ACCORDION) group also recently released follow-up data 
of the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial. Four-year outcomes of patients with type 2 DM 
were compared between a standard therapy group (goal HbA1c 
7.0–7.9%, mean HbA1c 7.7% during the study) and intensive 
glucose control group (goal HbA1c <6%, mean HbA1c 6.4%). 
Despite normalization after the study period, only 5.8% of 
Figure 1. Optical coherence tomography angiography image 
of a left eye in a patient with severe non-proliferative diabetic 
retinopathy, displaying enlargement and irregularity of the 
foveal avascular zone, and temporal capillary dropout.
intensive control patients had a three-step Early Treatment 
Diabetic Retinopathy Study (ETDRS) worsening, compared 
with 12.7% of standard therapy patients14. This interesting result 
suggests that there is a form of metabolic memory in diabetic 
patients, which confers a protective effect of even short periods 
of intense glycemic control. The ACCORDION group also looked 
at the effects of blood lipid composition and blood pressure, 
showing that intensive blood pressure control had no effect on 
DR progression but that treatment with feno brate did show a 
reduction in progression. The Feno brate on the Need for Laser 
Treatment for Diabetic Retinopathy (FIELD) study echoed these 
ndings, showing that patients taking feno brate had a reduced 
need for laser therapy. Interestingly, non-lipidic mechanisms 
appear to  have a more central role in this bene cial effect than 
lipidic  mechanisms15,16.
It is important to note, however, that the ACCORD study was 
halted prematurely when it appeared that all-cause mortality was 
greater in intensive glycemic control patients. It is apparent that 
cardiovascular disease was the primary cause of mortality, but the 
exact reason for this discrepancy remains unclear. This effect was 
not seen in similar studies, but polypharmacy has been suggested 
as a possible factor17. Based on the above studies, it is advisable 
to aim for an HbA1c of less than 7% and to avoid polypharmacy. 
Importantly though, glycemic goals need to be carefully individ-
ualized on the basis of the presence of additional comorbidities, 
expected longevity, and any other relevant factors.
Update on surgery and vitreolysis
Vitreoretinal surgery is the standard treatment of several ocular 
complications of DR. The treatment of choice for non-clearing 
vitreous hemorrhage remains pars plana vitrectomy. Diabetics 
can experience macular edema from vitreous traction or epireti-
nal membranes, both of which are surgically treated. Tractional 
retinal detachments (TRDs) threatening the macula and combined 
tractional-rhegmatogenous retinal detachments should be surgi-
cally repaired18, although more peripheral TRDs often can be 
carefully observed19. Diabetic patients with vitreomacular trac-
tion (VMT) may also bene t from surgical intervention. The 
DRCR.net investigated the ef cacy of pars plana vitrectomy and 
membrane peeling for patients with VMT and DME in Protocol D. 
The study found that nearly 40% of patients had a visual gain of at 
least 10 letters but that 22% had a worsening of at least 10 letters. 
This result was concurrent with a host of surgical complications 
like endophthalmitis (1.1%), vitreous hemorrhage (5.7%), and 
retinal detachment (3.4%)20. The recent advent of small-gauge 
vitrectomy may help stem these complications and potentially tip 
the balance toward earlier surgical intervention.
It has been shown that the presence of a posterior vitreous 
detachment (PVD) reduces the risk of proliferative diabetic 
retinopathy (PDR) development, likely because the posterior 
hyaloid and vitreous act as a scaffold for NV. Ocriplasmin is a  pro-
teolytic enzyme agent intended to non-surgically induce a PVD. 
A trial to investigate its use in patients with diabetes is under way21.
Non-clearing vitreous hemorrhage is a common complication of 
neovascular disease that is also treated surgically. The original 
Diabetic Retinopathy Vitrectomy Study showed that early vitrec-
tomy (that is, within six months compared with more than one 
year) can be useful, especially for type 1 diabetics22. Though the 
risks and bene ts of vitrectomy must be weighed in each case, 
earlier surgery can be helpful in immediately restoring vision, 
inducing a PVD, and providing pan-retinal photocoagulation to 
reduce disease burden23. Anti-VEGF agents have proven useful in 
the management of vitreous hemorrhage and have been shown to 
reduce the eventual need for vitrectomy24. Nevertheless, vitrectomy 
still has a role to play for non-clearing hemorrhage.
Retina surgeons have also incorporated the use of intravitreal 
VEGF inhibitors when repairing TRDs. In case series, preop-
erative anti-VEGF injections have been shown to improve 
outcomes in patients with TRD by regressing active retinal 
NV and  decreasing the likelihood of perioperative bleeding25. 
However, use of these agents has also been reported to exacer-
bate TRDs via the ‘crunch’ phenomenon, whereby brovascular 
contraction occurs26, making it more dif cult to separate tis-
sue planes27.  Newer techniques and devices have the potential to 
further improve the outcomes in patients with TRDs. Bimanual 
dissection techniques with chandelier lighting or an illuminated 
pick can be effective in repair of complex detachments and 
peeling membranes28. Additionally, mixed-gauge vitrectomy, with 
27-gauge instruments inserted through 24-gauge cannulas, can 
permit access to more of the retinal periphery in these complex 
cases29.
Update on laser
The landmark Diabetic Retinopathy Study demonstrated a 
reduction in severe vision loss in patients with high-risk PDR 
following prompt treatment with panretinal photocoagulation 
(PRP)30. The ETDRS originally demonstrated a 50% reduc-
tion in moderate vision loss in patients with clinically signi cant 
diabetic macular edema (CSME) who underwent immediate focal 
laser photocoagulation31. Moreover, among patients with PDR or 
severe non-proliferative diabetic retinopathy (NPDR), combined 
focal and scatter photocoagulation reduced severe vision loss 
by 50%. The DRCR.net Protocol K results revealed that among 
patients with a reduction in CSME 16 weeks after focal/grid laser 
treatment, 23–63% will continue to improve without further 
treatment32. PRP remains a mainstay of treatment for prolifera-
tive disease. Recently, the results of DRCR.net Protocol S were 
released, demonstrating that the anti-VEGF agent ranibizumab 
was non-inferior to PRP for the treatment of PDR. At two years of 
follow-up, about 53% of patients in the PRP group also received 
intravitreal ranibizumab for coexisting DME, demonstrating 
that combination treatment can be helpful in these situations33. 
How this will affect clinical practice patterns, especially in light 
of concerns surrounding cost and the inconvenience of regular 
intravitreal injections, remains to be seen. And while focal laser 
is still used by many practitioners, anti-VEGF agents have largely 
displaced it as the primary treatment of DME. There continues 
to be research into use of focal laser, especially in the form of 
non-damaging, or subthreshold, laser therapy, although to date 
this form has shown only marginal bene t compared with 
conventional laser34. Although many physicians currently use 
non-damaging laser, there remains to be a clear consensus on its 
preferred use.
Update on pharmacologics: ranibizumab
As mentioned previously, anti-VEGF agents are revolutioniz-
ing the management of DR. Intravitreal VEGF inhibitors are the 
rst-line agents to treat center-involving DME, and these agents 
have a growing use in control of proliferative disease as well. 
Ranibizumab (Lucentis, Genentech, South San Francisco, CA, 
USA) is the antigen-binding fragment of a humanized murine 
recombinant monoclonal antibody to VEGF-A35 and is US Food 
and Drug Administration (FDA)-approved for the treatment of 
DME and DR at a dose of 0.3 mg monthly.
The Ranibizumab for Diabetic Macular Edema (RIDE and 
RISE) trials investigated the use of monthly ranibizumab at two 
doses—0.5 and 0.3 mg—for the treatment of DME36. A secondary 
analysis of these data also examined the progression of DR 
in these patients using the diabetic retinopathy severity score 
(DRSS)37. In patients with NPDR or PDR, there was an at least 
three-step improvement in 15% and 13.2% of patients using 
monthly 0.3 or 0.5 mg injections at 36 months, respectively37. 
Only 3.3% of patients in the sham group achieved this result. The 
probabilities of progression to PDR in these patients were 39% 
in the sham group and 18.3% and 17.1% in the 0.3 and 0.5 mg 
groups, respectively.
Five hundred patients from RIDE and RISE were then offered 
ranibizumab 0.5 mg as needed, and outcomes at 48 months were 
examined. At 48 months, 11.2% and 7.6% of patients in the 
0.3 and 0.5 mg groups achieved an at least three-step DRSS 
improvement, respectively. The sham with crossover group, by 
comparison, saw this improvement in only 4.8%. Additionally, 
an at least two-step worsening occurred in 2.5% and 11.3% of 
ranibizumab and sham patients, respectively. Finally, patients 
originally in the ranibizumab groups had overall lower risk of 
PDR development than the sham group, a nding which per-
sisted to month 5437. An additional secondary analysis looked at 
FA results in the sham group and showed that when these patients 
were switched to ranibizumab, retinal non-perfusion was halted38. 
Overall, RIDE and RISE stressed the importance of early and 
regular therapy with ranibizumab.
The DRCR.net, mentioned above, also examined results of 
treatment of DME with combinations of laser, steroids, and anti-
VEGF in Protocol I. The study was a prospective randomized trial 
which divided patients with DME into four groups: sham injec-
tion plus focal laser (L), triamcinolone injection plus focal laser 
(T+L), ranibizumab with prompt laser (R+pL), and ranibizumab 
with deferred laser (R+dL)39. Further analysis then separated 
these groups into patients with and without PDR at the time of 
randomization40. For patients without PDR at baseline, worsen-
ing of retinopathy at 36 months was reported in 7%, 18%, 23%, 
and 37% of R+dL, R+pL, L, and T+L groups, respectively. 
Among patients with PDR at baseline, worsening of retinopathy at 
36 months was reported in 18%, 21%, 40%, and 12% among the 
same respective groups. Additionally, patients receiving injections of 
any kind (ranibizumab or triamcinolone) had lower rates of vitreous 
hemorrhage and were less likely to require PRP. The results are 
strong evidence that ranibizumab can help prevent progression of 
retinopathy.
As mentioned previously, DRCR.net Protocol S also showed 
that ranibizumab was non-inferior to PRP in patients with high-
risk PDR33. Additional 2016 data showed that patients with PDR 
treated with ranibizumab showed less progression than patients 
treated with PRP41. Ranibizumab was recently approved by the 
FDA for treatment of all forms of DR. It remains to be seen how 
the results of Protocol S combined with this approval will affect 
clinical practice patterns.
Update on pharmacologics: a ibercept
A ibercept (Eylea, Regeneron, Tarrytown, NY, USA), another 
widely used agent, is a fusion protein of the human IgG Fc region 
and the extracellular VEGF receptor ligand binding region, which 
binds to VEGF-A, VEGF-B, placental growth factor-1 (PlGF-1), 
and PlGF-235. It is FDA-approved for the treatment of DME and 
DR in patients with DME at a dose of 2 mg every eight weeks 
after ve initial monthly injections. It has been studied recently in 
the Intravitreal A ibercept for Diabetic Macular Edema (VISTA 
and VIVID) trials. In these trials, a ibercept was compared with 
focal laser for the treatment of DME42. These studies demon-
strated the superiority of a ibercept over laser in terms of visual 
acuity improvement and at least two-step improvement in DRSS. 
Patients were separated 1:1:1 into groups receiving focal laser, 
2 mg of intravitreal a ibercept every four weeks, or 2 mg every 
eight weeks. Both injection groups initially received ve months of 
monthly a ibercept injections. Patients in either a ibercept group 
were three times more likely to achieve at least two-step DRSS 
improvement than patients in the laser group. In both studies, 
baseline DRSS was correlated with the likelihood of at least 
two-step DRSS improvement.
A recent publication from the DRCR.net43 evaluated eyes 
enrolled in Protocol T and reviewed how their DRSS changed 
after treatment with a ibercept, bevacizumab, or ranibizumab. 
In this analysis, all three agents were effective in reducing DR. 
However, in the subset of eyes that had PDR at baseline, 
a ibercept was more effective in regressing the PDR than 
bevacizumab or ranibizumab.
Update on pharmacologics: bevacizumab
Bevacizumab (Avastin, Genentech) is a full-length humanized 
murine monoclonal antibody that binds to VEGF-A35. It is not 
FDA-approved for the treatment of DR or DME. The intravit-
real bevacizumab or laser therapy in the management of diabetic 
macular edema (BOLT) study examined the ef cacy of bevaci-
zumab versus focal laser for DME. Patients in the bevacizumab 
group showed signi cant best-corrected visual acuity (BCVA) 
improvement over patients in the laser group44. ETDRS retin-
opathy levels were also included and showed that patients in the 
bevacizumab arm trended toward DR reduction, although this 
effect was not statistically signi cant. This is likely due to the 
relatively small number of patients enrolled in the study. A recent 
comparative effectiveness randomized clinical trial conducted 
by the DRCR.net compared bevacizumab with ranibizumab and 
a ibercept for DME and found that all three agents are effective 
treatments, and this was con rmed on two-year follow-up45.
Anti–vascular endothelial growth factor summary
These and earlier trials of anti-VEGF agents are evidence that 
early and regular anti-VEGF treatment can halt and sometimes 
reverse DR. The reason for reversal is still unclear, and elucida-
tion of this mechanism may open the door to new therapies. 
Given that capillary non-perfusion and retinal ischemia may be 
the primary contributors to DME and DR progression at base-
line, it is possible that halting non-perfusion results in a reversal 
of the disease in some patients37. Knowing which patients will or 
will not bene t most from anti-VEGF treatment continues be an 
active area of research. It has been suggested that early positive 
response to anti-VEGF injections predicts outcome at three 
months46. Conversely, recent OCTA data showed that deep 
capillary plexus damage predicts poor response to treatment47. As 
with any invasive therapy, careful consideration of the risks and 
bene ts of repeated intravitreal injections is necessary for each 
patient. These risks include serious ophthalmic complications 
such as endophthalmitis and retinal detachment as well as 
potential systemic complications such as hypertension, proteinu-
ria, impaired wound healing, and increased risk of cardiovascular 
events48.
Update on dexamethasone and uocinolone acetonide
Despite the dominance of anti-VEGF agents, there is still a role 
to play for intravitreal corticosteroids. Steroids work by inhibit-
ing leukostasis, enhancing barrier function of tight junctions, and 
mitigating release of local in ammatory factors, including VEGF49. 
The Macular Edema: Assessment of Implantable Dexamethasone 
in Diabetes (MEAD) study examined the effectiveness of a dex-
amethasone implant versus sham for the treatment of DME. The 
implant groups (0.7 and 0.35 mg) had higher percentages of patients 
achieving at least 15 ETDRS letters gained at 3-year follow-up 
compared with the sham group (22%, 18%, and 12%, respectively). 
A pooled analysis of the MEAD study showed that patients in either 
implant group had a 12-month delay in two-step DR progression 
(36 versus 24 months) compared with sham patients50. As with 
most steroid treatments, development of cataract and intraocular 
pressure (IOP) elevation were the most common side effects.
Fluocinolone acetonide (Iluvien, Alimera Sciences, Alpharetta, 
GA, USA) is another corticosteroid implant that has treatment 
bene t for at least three years. The Fluocinolone Acetonide in 
Diabetic Macular Edema study evaluated low-dose (0.2 μg per 
day) and high-dose (0.5 μg per day) uocinolone implants in 
patients with DME who had received at least one laser treatment. 
At 36 months, 33% and 31.9% of patients in the low-dose and 
high-dose groups, respectively, had an improvement of 15 ETDRS 
letters or more, compared with 21.4% of sham patients. Of patients 
with a history of DME at least three years, 34% and 28.8% 
of low- and high-dose patients, respectively, gained 15 ETDRS 
letters or more, compared with 13.4% of sham patients. Moreover, 
an at least two-step improvement in DRSS occurred in 13.7% of 
low-dose and 10.1% of high-dose patients compared with 8.9% of 
sham patients. As with other steroid therapies, side effects included 
cataract and IOP elevation. IOP elevation was severe enough to 
require glaucoma tube shunt placement in less than 5% of low-dose 
patients and 8% of high-dose patients51.
The results of DRCR Protocol U will also soon be available. 
This study will assess the short-term effects of combination 
intravitreal dexamethasone and ranibizumab therapy in eyes with 
persistent DME despite prior anti-VEGF therapy compared with 
continued anti-VEGF therapy alone.
Summary of pharmacologic agents
The continued takeaway of these recent studies on pharmaco-
logic agents is that early treatment of DME in NPDR or PDR is 
vital to halt and sometimes reverse retinopathy. De-escalation of 
anti-VEGF treatment is sometimes possible without compromis-
ing initial gains, although this is more often the case when therapy 
has been initiated early. Corticosteroids are beginning to take a 
place as second-line therapy for patients unresponsive to anti- 
VEGF agents or focal laser or both. This is especially applicable for 
pseudophakic patients who have passed a steroid IOP challenge.
Conclusions
Despite the remarkable gains we have made in the treatment 
of DR and its complications, the primary strategy against this 
disease should be the ardent prevention of diabetes whenever pos-
sible. If diabetes is already present, tight glycemic control is the 
most important modality to prevent or control retinopathy, and 
control of other systemic factors such as lipid levels and blood 
pressure also plays an important role. New diagnostic approaches 
and imaging modalities may aid in capturing referable retinopa-
thy at earlier stages. Once retinopathy develops, early and regu-
lar treatment is crucial to prevent permanent vision loss. While 
there remains a place for laser and incisional surgery, the role of 
pharmaceutical agents has expanded in recent years. Anti-VEGF 
agents have become the rst-line agents for the treatment of 
center-involved DME. In addition, intravitreal VEGF inhibitors 
have been proven to be effective in regressing DR. Inhibition of 
VEGF has resulted in an effective treatment to preserve vision in 
patients with DR. Future treatment strategies might focus on less 
invasive delivery methods or alternative therapeutic targets. In 
the early stages of DR, when neurodegeneration plays an impor-
tant role, intravitreal anti-VEGF injections may represent an 
overly aggressive approach. In these situations, topically deliv-
ered therapies, such as endogenous neuroprotective substances, 
hold exciting promise52. Along with the continued vigilance 
of clinicians, the expanding armamentarium of diagnostic and 
therapeutic options for DR will be an invaluable tool in the ght to 
reduce the impact of this devastating disease.
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